Medlab Clinical (ASX:MDC) 3-Year Revenue Growth Rate : -40.90% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Medlab Clinical 3-Year Revenue Growth Rate?

Medlab Clinical's Revenue per Share for the six months ended in Dec. 2023 was A$0.02.

During the past 12 months, Medlab Clinical's average Revenue per Share Growth Rate was -76.30% per year. During the past 3 years, the average Revenue per Share Growth Rate was -40.90% per year. During the past 5 years, the average Revenue per Share Growth Rate was -3.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 8 years, the highest 3-Year average Revenue per Share Growth Rate of Medlab Clinical was 179.90% per year. The lowest was -40.90% per year. And the median was -11.60% per year.

Competitive Comparison of Medlab Clinical's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Medlab Clinical's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medlab Clinical's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medlab Clinical's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Medlab Clinical's 3-Year Revenue Growth Rate falls into.

Medlab Clinical 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Medlab Clinical (ASX:MDC) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Medlab Clinical 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Medlab Clinical's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Medlab Clinical (ASX:MDC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medlab Clinical Ltd (ASX:MDC) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

11 Lord Street, Unit 5, Botany, NSW, AUS, 2019

Website

https://www.medlab.co

Medlab Clinical Ltd is a medical research and development company. It is engaged in researching and formulating novel biotherapeutics to improve health outcomes in early to moderate stage chronic diseases such as chronic kidney disease, pre-diabetes, and obesity. Some of the company's nutraceutical products are Multibiotic, Mg Optima Relax, NRGBiotic, NanoCelle D3, SB 5B and others. The principal segments of the group are Nutraceutical which includes the sale of nutraceutical products; and Pharmaceutical research. It generates the majority of the revenue from the sale of nutraceutical products. The business operations of the firm are carried out from Australia.